ConductScience.org, home

Disease · MONDO_0020333

aggressive systemic mastocytosis

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. aggressive systemic mastocytosis. Diseases, record MONDO_0020333. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020333

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
aggressive systemic mastocytosis
Open Targets
Open Targets ID
MONDO_0020333
Open Targets
Other names
ASM, aggressive systemic mastocytosis (morphologic abnormality)
Open Targets
Disease Ontology
DOID:4798
Disease Ontology
NCI Thesaurus
C9285
NCI Thesaurus
Orphanet
ORPHA:98850
Orphanet
Highest stage of its drugs
Phase 2, for its one drug, from ClinicalTrials.gov
Open Targets

Drugs1

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown here
MIDOSTAURINCHEMBL608533Small moleculePhase 2ClinicalTrials.gov333

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
FLT3Receptor-type tyrosine-protein kinase FLT31Tyrosine-protein kinase receptor FLT3 inhibitorPhase 2https://conductscience.org/library/genes/2322Drugs and targets
KDRVascular endothelial growth factor receptor 21Vascular endothelial growth factor receptor 2 inhibitorPhase 2https://conductscience.org/library/genes/3791Drugs and targets
KITMast/stem cell growth factor receptor Kit1Stem cell growth factor receptor inhibitorPhase 2https://conductscience.org/library/genes/3815Drugs and targets
PDGFRAPlatelet-derived growth factor receptor1Platelet-derived growth factor receptor inhibitorPhase 2https://conductscience.org/library/genes/5156Drugs and targets
PDGFRBPlatelet-derived growth factor receptor1Platelet-derived growth factor receptor inhibitorPhase 2https://conductscience.org/library/genes/5159Drugs and targets
PRKCAProtein kinase C (PKC)1Protein kinase C (PKC) inhibitorPhase 2https://conductscience.org/library/genes/5578Drugs and targets
PRKCBProtein kinase C (PKC)1Protein kinase C (PKC) inhibitorPhase 2https://conductscience.org/library/genes/5579Drugs and targets
PRKCDProtein kinase C (PKC)1Protein kinase C (PKC) inhibitorPhase 2https://conductscience.org/library/genes/5580Drugs and targets
PRKCEProtein kinase C (PKC)1Protein kinase C (PKC) inhibitorPhase 2https://conductscience.org/library/genes/5581Drugs and targets
PRKCGProtein kinase C (PKC)1Protein kinase C (PKC) inhibitorPhase 2https://conductscience.org/library/genes/5582Drugs and targets

1 to 10 of 16

See all 16 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00782067Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell LeukemiaPhase 21162017-06-06LeukemiaMIDOSTAURINIts record names the diseaseClinicalTrials.gov
NCT00233454Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaPhase 2262015-07-09Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)MIDOSTAURINIts record names the diseaseClinicalTrials.gov
NCT05219266Managed Access Programs for PKC412, Midostaurin
FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia, Acute Myeloid Leukemia, Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis With an Associated Hematologic Neoplasm
MIDOSTAURINIts record names the diseaseClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
28744009RESULT1PubMed
27355533RESULT2PubMed
39649724DERIVED1PubMed
32437738DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020333

GET https://conductscience.org/api/diseases/v1/MONDO_0020333/drugs